Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Ocuphire Pharma Inc OCUP

Healthcare
Ocuphire Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. The Company’s lead retinal product candidate, APX3330, is a small-molecule inhibitor of Ref-1 (reduction oxidation effector factor-1 protein). Ref1 is a regulator of transcription factors such as HIF-1a... see more

Recent & Breaking News (NDAQ:OCUP)

Rexahn Pharmaceuticals Announces Publication of Preclinical Data for RX-3117 Demonstrating Effectiveness Against Gemcitabine Resistant Human Cancer Cells

GlobeNewswire January 6, 2015

Rexahn Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 10, 2014

GlobeNewswire December 4, 2014

Rexahn Pharmaceuticals Appoints Richard Rodgers to Its Board of Directors

GlobeNewswire December 3, 2014

Rexahn Pharmaceuticals to Participate in Brean Capital 2014 Life Sciences Summit

GlobeNewswire November 17, 2014

Rexahn Pharmaceuticals Reports Third Quarter 2014 Financial Results and Pipeline Update

GlobeNewswire November 13, 2014

Rexahn Pharmaceuticals to Present at the Stifel 2014 Healthcare Conference on November 18, 2014

GlobeNewswire November 11, 2014

Rexahn Pharmaceuticals to Present at the BIO-Europe(R) Conference in Frankfurt, Germany

GlobeNewswire October 28, 2014

Rexahn Pharmaceuticals to Present at 13th Annual BIO Investor Forum

GlobeNewswire September 30, 2014

Rexahn Receives FDA Orphan Drug Designation for RX-3117 in Treatment of Pancreatic Cancer

GlobeNewswire September 24, 2014

Rexahn Pharmaceuticals to Present at the 14th Annual Biotech in Europe Investor Forum for Global Partnering and Investment in Basel, Switzerland

GlobeNewswire September 23, 2014

Rexahn Pharmaceuticals to Present at the BioPharm America(TM) 2014 in Boston, Massachusetts, USA

Business Wire September 16, 2014

Rexahn Pharmaceuticals to Present at the 16th Annual Rodman & Renshaw Global Investment Conference on September 9, 2014

Business Wire September 4, 2014

Rexahn Receives a Notice of Allowance from the U.S. Patent and Trademark Office for a Novel Targeted Cancer Drug Delivery Platform

Business Wire September 3, 2014

Rexahn Pharmaceuticals Reports Second Quarter 2014 Financial Results and Pipeline Update

Business Wire August 14, 2014

Rexahn Pharmaceuticals Provides Update on Phase I Supinoxin Trial in Cancer Patients with Solid Tumors

Business Wire July 18, 2014

How the Lack of R&D at Big Pharma Is Boosting Small Biotechs

Equities.com June 14, 2014

Three biotechs stocks with positive institutional transactions, good price to cash ratios and "buy" recommendations from street analysts

Accesswire May 22, 2014

Rexahn Pharmaceuticals Reports First Quarter 2014 Financial Results and Pipeline Update

Business Wire May 15, 2014

Rexahn Announces Additional Data from Preclinical Studies of RX-3117

Business Wire May 8, 2014

Rexahn Presents Data from Preclinical Studies of RX-21101

Business Wire April 21, 2014